AUSTIN, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vetty, the one-stop shop hiring acceleration platform, announced today that it was…
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial…
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
December 07, 2025 16:00 ET | Source: Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) --…
New York, NY, Dec. 06, 2025 (GLOBE NEWSWIRE) -- RadiantVibe Capital Consortium today announced the debut of its new Insight…
New York, USA, Dec. 06, 2025 (GLOBE NEWSWIRE) -- BI DeFi has officially launched its new Daily Yield Plan, expanding…
December 05, 2025 16:00 ET | Source: Humanoid Global Holdings Corp. – NOT FOR DISSEMINATION IN THE UNITED STATES OR…
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…